These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

570 related articles for article (PubMed ID: 26119939)

  • 21. Pomalidomide restores immune recognition of primary effusion lymphoma through upregulation of ICAM-1 and B7-2.
    Shrestha P; Davis DA; Jaeger HK; Stream A; Aisabor AI; Yarchoan R
    PLoS Pathog; 2021 Jan; 17(1):e1009091. PubMed ID: 33411730
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activated Nrf2 Interacts with Kaposi's Sarcoma-Associated Herpesvirus Latency Protein LANA-1 and Host Protein KAP1 To Mediate Global Lytic Gene Repression.
    Gjyshi O; Roy A; Dutta S; Veettil MV; Dutta D; Chandran B
    J Virol; 2015 Aug; 89(15):7874-92. PubMed ID: 25995248
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels.
    Greenberg AJ; Walters DK; Kumar SK; Rajkumar SV; Jelinek DF
    Eur J Haematol; 2013 Dec; 91(6):504-13. PubMed ID: 23992230
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dissecting the impact of bromodomain inhibitors on the Interferon Regulatory Factor 4-MYC oncogenic axis in multiple myeloma.
    Agnarelli A; Mitchell S; Caalim G; Wood CD; Milton-Harris L; Chevassut T; West MJ; Mancini EJ
    Hematol Oncol; 2022 Aug; 40(3):417-429. PubMed ID: 35544413
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma.
    Moros A; Rodríguez V; Saborit-Villarroya I; Montraveta A; Balsas P; Sandy P; Martínez A; Wiestner A; Normant E; Campo E; Pérez-Galán P; Colomer D; Roué G
    Leukemia; 2014 Oct; 28(10):2049-59. PubMed ID: 24721791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of BRD4 suppresses tumor growth in prostate cancer via the enhancement of FOXO1 expression.
    Tan Y; Wang L; Du Y; Liu X; Chen Z; Weng X; Guo J; Chen H; Wang M; Wang X
    Int J Oncol; 2018 Dec; 53(6):2503-2517. PubMed ID: 30272279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biscoclaurine alkaloid cepharanthine inhibits the growth of primary effusion lymphoma in vitro and in vivo and induces apoptosis via suppression of the NF-kappaB pathway.
    Takahashi-Makise N; Suzu S; Hiyoshi M; Ohsugi T; Katano H; Umezawa K; Okada S
    Int J Cancer; 2009 Sep; 125(6):1464-72. PubMed ID: 19521981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma.
    Zhang X; Lee HC; Shirazi F; Baladandayuthapani V; Lin H; Kuiatse I; Wang H; Jones RJ; Berkova Z; Singh RK; Lu J; Qian Y; Raina K; Coleman KG; Crews CM; Li B; Wang H; Hailemichael Y; Thomas SK; Wang Z; Davis RE; Orlowski RZ
    Leukemia; 2018 Oct; 32(10):2224-2239. PubMed ID: 29581547
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diallyl trisulfide induces apoptosis by suppressing NF-κB signaling through destabilization of TRAF6 in primary effusion lymphoma.
    Shigemi Z; Furukawa Y; Hosokawa K; Minami S; Matsuhiro J; Nakata S; Watanabe T; Kagawa H; Nakagawa K; Takeda H; Fujimuro M
    Int J Oncol; 2016 Jan; 48(1):293-304. PubMed ID: 26647777
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of anti-CD47 antibody-mediated phagocytosis with macrophages against primary effusion lymphoma.
    Goto H; Kojima Y; Matsuda K; Kariya R; Taura M; Kuwahara K; Nagai H; Katano H; Okada S
    Eur J Cancer; 2014 Jul; 50(10):1836-1846. PubMed ID: 24726056
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting mTOR with MLN0128 Overcomes Rapamycin and Chemoresistant Primary Effusion Lymphoma.
    Caro-Vegas C; Bailey A; Bigi R; Damania B; Dittmer DP
    mBio; 2019 Feb; 10(1):. PubMed ID: 30782662
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression.
    Zhang LH; Kosek J; Wang M; Heise C; Schafer PH; Chopra R
    Br J Haematol; 2013 Feb; 160(4):487-502. PubMed ID: 23252516
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Triptolide decreases expression of latency-associated nuclear antigen 1 and reduces viral titers in Kaposi's sarcoma-associated and herpesvirus-related primary effusion lymphoma cells.
    Long C; Guo W; Zhou H; Wang J; Wang H; Sun X
    Int J Oncol; 2016 Apr; 48(4):1519-30. PubMed ID: 26821279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression.
    Li GQ; Guo WZ; Zhang Y; Seng JJ; Zhang HP; Ma XX; Zhang G; Li J; Yan B; Tang HW; Li SS; Wang LD; Zhang SJ
    Oncotarget; 2016 Jan; 7(3):2462-74. PubMed ID: 26575167
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs.
    Gemechu Y; Millrine D; Hashimoto S; Prakash J; Sanchenkova K; Metwally H; Gyanu P; Kang S; Kishimoto T
    Proc Natl Acad Sci U S A; 2018 Nov; 115(46):11802-11807. PubMed ID: 30373817
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Co-targeting BET bromodomain BRD4 and RAC1 suppresses growth, stemness and tumorigenesis by disrupting the c-MYC-G9a-FTH1axis and downregulating HDAC1 in molecular subtypes of breast cancer.
    Ali A; Shafarin J; Unnikannan H; Al-Jabi N; Jabal RA; Bajbouj K; Muhammad JS; Hamad M
    Int J Biol Sci; 2021; 17(15):4474-4492. PubMed ID: 34803511
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunomodulatory drugs act as inhibitors of DNA methyltransferases and induce PU.1 up-regulation in myeloma cells.
    Endo S; Amano M; Nishimura N; Ueno N; Ueno S; Yuki H; Fujiwara S; Wada N; Hirata S; Hata H; Mitsuya H; Okuno Y
    Biochem Biophys Res Commun; 2016 Jan; 469(2):236-42. PubMed ID: 26657848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pyrrolidinium fullerene induces apoptosis by activation of procaspase-9 via suppression of Akt in primary effusion lymphoma.
    Watanabe T; Nakamura S; Ono T; Ui S; Yagi S; Kagawa H; Watanabe H; Ohe T; Mashino T; Fujimuro M
    Biochem Biophys Res Commun; 2014 Aug; 451(1):93-100. PubMed ID: 25063029
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer.
    Mao F; Li J; Luo Q; Wang R; Kong Y; Carlock C; Liu Z; Elzey BD; Liu X
    Mol Cancer Ther; 2018 Jul; 17(7):1554-1565. PubMed ID: 29716963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bromodomain protein BRD4 promotes cell proliferation in skin squamous cell carcinoma.
    Xiang T; Bai JY; She C; Yu DJ; Zhou XZ; Zhao TL
    Cell Signal; 2018 Jan; 42():106-113. PubMed ID: 29050985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.